Primary Dysmenorrhea: Assessment and Treatment

Inês Guimarães, Ana Margarida Póvoa, Inês Guimarães, Ana Margarida Póvoa

Abstract

Primary dysmenorrhea is defined as menstrual pain in the absence of pelvic disease. It is characterized by overproduction of prostaglandins by the endometrium, causing uterine hypercontractility that results in uterine muscle ischemia, hypoxia, and, subsequently, pain. It is the most common gynecological illness in women in their reproductive years and one of the most frequent causes of pelvic pain; however, it is underdiagnosed, undertreated, and even undervalued by women themselves, who accept it as part of the menstrual cycle. It has major implications for quality of life, such as limitation of daily activities and psychological stress, being one of the main causes of school and work absenteeism. Its diagnosis is essentially clinical, based on the clinical history and normal physical examination. It is important to exclude secondary causes of dysmenorrhea. The treatment may have different approaches (pharmacological, non-pharmacological and surgical), but the first line of treatment is the use of nonsteroidal anti-inflammatory drugs (NSAIDs), and, in cases of women who want contraception, the use of hormonal contraceptives. Alternative treatments, such as topical heat, lifestyle modification, transcutaneous electrical nerve stimulation, dietary supplements, acupuncture, and acupressure, may be an option in cases of conventional treatments' contraindication. Surgical treatment is only indicated in rare cases of women with severe dysmenorrhea refractory to treatment.

Conflict of interest statement

The authors have no conflict of interests to declare.

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).

Figures

Fig. 1
Fig. 1
Prostaglandin synthesis pathway. Abbreviations: 5-HPETE, arachidonic acid 5-hydroperoxide; PGF 2a, prostaglandin F 2a ; PGE 2 , prostaglandin E 2 ; PGG 2 , prostaglandin G 2 ; PGH 2 , prostaglandin H 2 .
Fig. 2
Fig. 2
Flowchart on the treatment of dysmenorrhea. Abbreviations: NSAIDs, non-steroidal anti-inflammatory; IUS-intrauterine system; LUNA, laparoscopic uterosacral nerve ablation; PSN, presacral neurectomy.

References

    1. Iacovides S, Avidon I, Baker F C.What we know about primary dysmenorrhea today: a critical review Hum Reprod Update 20152106762–778.. Doi: 10.1093/humupd/dmv039
    1. Burnett M, Lemyre . 345-primary dysmenorrhea consensus guideline J Obstet Gynaecol Can 20173907585–595.. Doi: 10.1016/j.jogc.2016.12.023
    1. Dawood M Y.Primary dysmenorrhea: advances in pathogenesis and management Obstet Gynecol 200610802428–441.. Doi: 10.1097/01.AOG.0000230214.26638.0c
    1. Osayande A S, Mehulic S. Diagnosis and initial management of dysmenorrhea. Am Fam Physician. 2014;89(05):341–346.
    1. Doty E, Attaran M.Managing primary dysmenorrhea J Pediatr Adolesc Gynecol 20061905341–344.. Doi: 10.1016/j.jpag.2006.06.005
    1. ACOG Committee Opinion No. 760: dysmenorrhea and endometriosis in the adolescent Obstet Gynecol 201813206e249–e258.. Doi: 10.1097/AOG.0000000000002978
    1. French L. Dysmenorrhea. Am Fam Physician. 2005;71(02):285–291.
    1. Harel Z.Dysmenorrhea in adolescents and young adults: an update on pharmacological treatments and management strategies Expert Opin Pharmacother 201213152157–2170.. Doi: 10.1517/14656566.2012.725045
    1. Morrow C, Naumburg E H.Dysmenorrhea Prim Care 2009360119–32, vii.. Doi: 10.1016/j.pop.2008.10.004
    1. Latthe P, Latthe M, Say L, Gülmezoglu M, Khan K S.WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity BMC Public Health 20066177. Doi: 10.1186/1471-2458-6-177
    1. Zahradnik H P, Hanjalic-Beck A, Groth K.Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review Contraception 20108103185–196.. Doi: 10.1016/j.contraception.2009.09.014
    1. Rodrigues A C, Gala S, Neves Â, Pinto C, Meirelles C, Frutuoso C, Vítor M E.Dismenorreia em adolescentes e jovens adultas: prevalência, factores associados e limitações na vida diária Acta Med Port 20112402383–388., quiz 389–392
    1. National Sleep Foundation [Internet] Women and sleep poll 1998[cited 2019 Jul 18]. Available from:
    1. French L.Dysmenorrhea in adolescents: diagnosis and treatment Paediatr Drugs 200810011–7.. Doi: 10.2165/00148581-200810010-00001
    1. Ryan S A.The treatment of dysmenorrhea Pediatr Clin North Am 20176402331–342.. Doi: 10.1016/j.pcl.2016.11.004
    1. Granot M, Yarnitsky D, Itskovitz-Eldor J, Granovsky Y, Peer E, Zimmer E Z.Pain perception in women with dysmenorrhea Obstet Gynecol 20019803407–411.. Doi: 10.1016/s0029-7844(01)01465-x
    1. Bajaj P, Bajaj P, Madsen H, Arendt-Nielsen L.A comparison of modality-specific somatosensory changes during menstruation in dysmenorrheic and nondysmenorrheic women Clin J Pain 20021803180–190.. Doi: 10.1097/00002508-200205000-00007
    1. Tu C H, Niddam D M, Chao H T, Chen L F, Chen Y S, Wu Y T.Brain morphological changes associated with cyclic menstrual pain Pain 201015003462–468.. Doi: 10.1016/j.pain.2010.05.026
    1. Yu A.Complementary and alternative treatments for primary dysmenorrhea in adolescents Nurse Pract 201439111–12.. Doi: 10.1097/01.NPR.0000454984.19413.28
    1. Ju H, Jones M, Mishra G.The prevalence and risk factors of dysmenorrhea Epidemiol Rev 201436104–113.. Doi: 10.1093/epirev/mxt009
    1. Xu K, Chen L, Fu L.Stressful parental-bonding exaggerates the functional and emotional disturbances of primary dysmenorrhea Int J Behav Med 20162304458–463.. Doi: 10.1007/s12529-015-9504-0
    1. Chen C X, Kwekkeboom K L, Ward S E.Self-report pain and symptom measures for primary dysmenorrhoea: a critical review Eur J Pain 20151903377–391.. Doi: 10.1002/ejp.556
    1. Smith R P, Kaunitz A M.Dysmenorrhea in adult women: treatment [Internet] 2019[cited 2019 Mar 10]. Available from:
    1. Harel Z.Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea J Pediatr Adolesc Gynecol 2004170275–79.. Doi: 10.1016/j.jpag.2004.01.002
    1. Trussell J.Contraceptive failure in the United States Contraception 20118305397–404.. Doi: 10.1016/j.contraception.2011.01.021
    1. Roumen F J.The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials Contraception 20077506420–429.. Doi: 10.1016/j.contraception.2007.01.013
    1. Morgan P J, Kung R, Tarshis J.Nitroglycerin as a uterine relaxant: a systematic review J Obstet Gynaecol Can 20022405403–409.. Doi: 10.1016/s1701-2163(16)30403-0
    1. Andersson K E, Ulmsten U.Effects of nifedipine on myometrial activity and lower abdominal pain in women with primary dysmenorrhoea Br J Obstet Gynaecol 19788502142–148.. Doi: 10.1111/j.1471-0528.1978.tb10469.x
    1. Armour M, Ee C C, Naidoo D, Ayati Z, Chalmers K J, Steel K A.Exercise for dysmenorrhoea Cochrane Database Syst Rev 20199CD004142. Doi: 10.1002/14651858.CD004142.pub4
    1. Pattanittum P, Kunyanone N, Brown J, Sangkomkamhang U S, Barnes J, Seyfoddin V, Marjoribanks J.Dietary supplements for dysmenorrhoea Cochrane Database Syst Rev 20163CD002124. Doi: 10.1002/14651858.CD002124.pub2
    1. Zhang F, Sun M, Han S, Shen X, Luo Y, Zhong D.Acupuncture for primary dysmenorrhea: an overview of systematic reviews Evid Based Complement Alternat Med 201820188.791538E6. Doi: 10.1155/2018/8791538
    1. Smith C A, Armour M, Zhu X, Li X, Lu Z Y, Song J.Acupuncture for dysmenorrhoea Cochrane Database Syst Rev 20164CD007854. Doi: 10.1002/14651858.CD007854.pub3
    1. Ramirez C, Donnellan N.Pelvic denervation procedures for dysmenorrhea Curr Opin Obstet Gynecol 20172904225–230.. Doi: 10.1097/GCO.0000000000000379

Source: PubMed

3
订阅